Objective To investigate the risk factors for poor short-term prognosis of patients with hepatic encephalopathy (HE) .Methods A retrospective analysis was performed for the clinical data of 316 patients with HE who were hospitalized and treated in The First Hospital of Jilin University from January 2013 to December 2015, and according to their prognosis, they were divided into survival group (229patients) and death group (87 patients) .The univariate and multivariate analyses were performed for their general data and biochemical parameters to screen out the risk factors for poor prognosis of HE.The t-test or Mann-Whitney U test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups.The multivariate logistic regression analysis was performed for the variables with statistical significance identified in the univariate analysis.Results All the patients were followed up for 30 days, and 87 patients died, resulting in a mortality rate of 27.5%.The male/female ratio was 1.72∶ 1, and 269 patients (85.13%) were aged ≥45 years.The univariate analysis showed that there were significant differences between the two groups in age, a combination of primary liver cancer, HE stage, white blood cell count, neutrophil count, hemoglobin, platelet count, international normalized ratio, prothrombin time, prothrombin time activity (PTA) , blood urea nitrogen, creatinine, serum sodium, serum potassium, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, albumin, indirect bilirubin, total bilirubin (TBil) , and prealbumin (all P<0.05) .The multivariate analysis showed that a combination of primary liver cancer (OR=3.278, 95% CI: 1.494-7.194, P=0.003) , HE stage (OR=2.402, 95% CI: 1.711-3.372, P<0.001) , PTA (OR=0.969, 95% CI:0.951-0.988, P=0.001) , serum sodium (OR=0.956, 95% CI: 0.922-0.992, P=0.018) , and TBil (OR=1.004, 95% CI:1.003-1.006, P<0.001) were independent risk factors for the prognosis of patients with HE.Conclusion A combination of primary liver cancer, advanced HE stage, low serum sodium, low PTA, and increased TBil are independent risk factors for poor prognosis of HE, and the equation based on these indices has a certain reference value in clinical practice.
[1]VOLK ML, TOCCO RS, BAZICK J, et al.Hospital readmissions among patients with decompensated cirrhosis[J].Am J Gastroenterol, 2012, 107 (2) :247-252.
|
[2]BUSTAMANTE J, RIMOLA A, VENTURA PJ, et al.Prognostic significance of hepatic encephalopathy in patients with cirrhosis[J].J Hepatol, 1999, 30 (5) :890-895.
|
[3]Chinese Society of Gastroenterology and Chinese Seciety of Hepatology, Chinese Medical Association.Consensus on the diagnosis and treatment of hepatic encephalopathy in China (Chongqing, 2013) [J/CD].Chin J Front Med Sci:Electronic Version, 2014, 6 (2) :81-93. (in Chinese) 中华医学会肝病学会会, 中华医学会消化学分会.中国肝性脑病诊治共识意见 (2013年, 重庆) [J/CD].中国医学前沿杂志:电子版, 2014, 6 (2) :81-93.
|
[4]YU YH, JIANG JN, WU JZ, et al.Prognostic factors for patients with hepatic encephalopathy:a logistic regression analysis[J].Chin J Infect Dis, 2009, 27 (5) :305-307. (in Chinese) 玉艳红, 江建宁, 吴继周, 等.肝性脑病患者预后影响因素的Logistic回归分析[J].中华传染病杂志, 2009, 27 (5) :305-307.
|
[5]CUI YP, LI QF, LI QY, et al.Logistic regression analysis of prognostic risk factors for hepatic encephalopathy[J].J Clin Hepatol, 2016, 32 (1) :135-138. (in Chinese) 崔燕平, 李庆方, 李庆彦, 等.肝硬脑病患者的预后影响因素分析[J].临床肝胆病杂志, 2016, 32 (1) :135-138.
|
[6]WONG PY, XIA V, IMAGAWA DK, et al.Clinical presentation of hepatocellular carcinoma (PLC) in Asian-Americans versus nonAsian-Americans[J].Immigr Minor Health, 2011, 13 (5) :842-848.
|
[7]KIM WR, BIGGINS SW, KREMERS WK, et al.Hyponatremia and mortality among patients on the liver-transplant waiting list[J].N Engl J Med, 2008, 359 (10) :1018-1026.
|
[8]GUEVARA M, BACCARO ME, TORRE A, et al.Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis:a prospective study with time-dependent analysis[J].Am J Gastroenterol, 2009, 104 (6) :1382-1389.
|
[9]CICHOZ-LACH H, MICHALAK A.Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy[J].World J Gastroenterol, 2013, 19 (1) :26-34.
|
[10]CORDOBA J, VENTURA-COTS M, SIMN-TALERO M, et al.Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF) [J].Hepatol, 2014, 60 (2) :275-281.
|
[11]UDAYAKUMAR N, SUBRAMANIAM K, UMASHANKAR L, et al.Predictors of mortality in hepatic encephalopathy in acute and chronic liver disease:a preliminary observation[J].Clin Gastroenterol, 2007, 41 (10) :922-926.
|
[12]SHARMA P, AGRAWAL A, SHARMA BC, et al.Prophylaxis of hepatic encephalopathy in acute variceal bleed:a randomized controlled trial of lactulose versus no lactulose[J].Gastroenterol Hepatol, 2011, 26 (6) :996-1003.
|
[13]AN H, JANG J, BAE S, et al.Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma[J].Liver Transpl, 2012, 18 (12) :1406-1414.
|
[14]PAPP M, VITALIS Z, ALTORJAY I, et al.Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections[J].Liver Int, 2012, 32 (4) :603-611.
|
[15]WONG F, BERNARDI M, BALK R, et al.Sepsis in cirrhosis:report on the 7th meeting of the International Ascites Club[J].Gut, 2005, 54 (5) :718-725.
|
[16]FERNNDEZ J, GUSTOT T.Management of bacterial infections in cirrhosis[J].Hepatol, 2012, 56 (1) :1-12.
|
1. | 张连峰,杨丽敏. 胸腺肽肠溶片联合聚乙二醇干扰素对慢性肝炎患者的治疗效果及其相关指标的影响. 中国当代医药. 2020(04): 50-52 . ![]() | |
2. | 王雪云,孙敏,赵巧云,李红军,王先芝,郑玉山,边城. 聚乙二醇干扰素联合富马酸替诺福韦治疗慢性乙型肝炎的疗效观察. 医学信息. 2020(04): 144-146 . ![]() | |
3. | 刘征. 恩替卡韦联合α-干扰素对慢性乙型肝炎患者血清ALT复常率的影响. 淮海医药. 2020(02): 181-183 . ![]() | |
4. | 李淑,彭雁忠,胡国信,齐明华,武敬. 聚乙二醇干扰素治疗低水平HBsAg慢性乙肝患者疗效. 中国热带医学. 2020(07): 676-681 . ![]() | |
5. | 嵇玮嘉,颜学兵. 聚乙二醇干扰素α-2a与聚乙二醇干扰素α-2b治疗慢性乙型肝炎的效果及安全性比较. 临床肝胆病杂志. 2019(02): 309-314 . ![]() | |
6. | 吴明杰. 聚乙二醇干扰素α-2b对慢性乙型肝炎的作用分析. 中国继续医学教育. 2019(12): 142-144 . ![]() | |
7. | 张珊,王艺璇,孙静,朱琳,王凤水,邢卉春. 干扰素联合抗病毒治疗对提高核苷(酸)类药物经治慢性乙型肝炎患者表面抗原阴转率的影响. 中华实验和临床感染病杂志(电子版). 2019(04): 273-280 . ![]() | |
8. | 郭志勇,贺文娟,裴军芳. 聚乙二醇干扰素α-2a注射液联合替诺福韦酯治疗e抗原阳性慢性乙型肝炎疗效分析. 中国药物与临床. 2019(22): 3944-3946 . ![]() |